What CRS does

CRS is a Mannheim, Germany-based clinical pharmacology services organization founded in 2006, providing Phase I clinical conduct, bioanalytical laboratory services, and clinical data management to pharmaceutical, biotechnology, and academic clients across Europe. The company operates clinical pharmacology units within an integrated life sciences services platform, with 51-100 employees supporting Phase I/early-phase clinical development including volunteer recruitment, bioanalysis, and data operations.

Following its January 2025 acquisition by hVIVO Services Limited (a public company listed on the London Stock Exchange AIM Market under ticker HVO), CRS now operates as a wholly-owned subsidiary within the hVIVO Group alongside Venn Life Sciences (drug development consulting) and Cryostore (HTA-licensed cryostorage and biobanking). The group was unified under the single hVIVO brand in 2025, presenting an integrated end-to-end early-phase clinical development platform spanning preclinical consultancy through Phase III delivery.

The combined platform serves global biopharma and emerging biotech companies via enterprise field sales and dedicated recruitment infrastructure including FluCamp (UK) and Probandeninfo (Germany), which provide access to a combined volunteer database of 400k+ trial participants. Revenue is generated through professional services and managed-services agreements covering six service lines: Clinical Trial Solutions, Drug Development Consulting, Human Challenge Solutions (with proprietary challenge models for RSV, Influenza, COVID-19, HRV, hMPV, Malaria, and Asthma/COPD), Laboratory Solutions, Integrated Solutions, and Biobank and Storage Solutions. Customer segments are diversified across global pharma, biotech, other CROs, start-ups, and drug development investors, with no single customer or segment concentration disclosed in the available data.

Name

CRS

Legal name

hVIVO Services Limited

Website

https://crs-group.de

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

51–100 employees

Short description

CRS is a Mannheim-based clinical pharmacology services provider delivering Phase I clinical conduct, bioanalytical laboratory services, and data management to biopharma clients. Acquired by hVIVO in January 2025, it now operates as a wholly-owned subsidiary within an integrated early-phase CRO platform.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Management Consulting Services (8742)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical research services
• Early phase clinical trials
• Drug development consulting
• Human challenge trials
• Bioanalytical laboratory services

Headquarters

HQ city

Mannheim

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Trial Services: Full-service clinical trial delivery across Phase I-III, including clinical pharmacology early phase, Phase I units, and Phase II/III studies. Services include data management, medical monitoring, medical writing, project management, quality assurance, recruitment, regulatory affairs, clinical trial sites, and biostatistics.
2. Drug Development Consulting: Strategic and scientific consulting services including clinical PK/PD, statistics and study design, CMC consulting, non-clinical development, regulatory affairs consultancy, due diligence, and medical writing.
3. Human Challenge Trial Services: World-leading human challenge models generating early efficacy data for accelerated decision-making, including virus production and characterisation, laboratory services, participant screening and recruitment, and clinical delivery.
4. Laboratory Services: Advanced laboratory services including bioanalysis, virology, immunology, molecular biology, PBMC processing, microbiology, and biomarker analysis. Also includes preclinical PK/PD studies, assay development and validation.
5. Cryostorage and Biobanking: HTA-licensed cryostorage and biobanking services with multi-temperature storage, 24/7 monitoring, full chain-of-custody management, and fast local access for biotech, pharma, and research partners.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

CRS is a group of Clinical Pharmacology Units that delivers clinical research services in drug development, bioanalytics, and data management. Following its January 2025 acquisition by hVIVO, CRS now operates within an integrated early-phase clinical development platform offering Phase I–III clinical trial delivery, drug development consulting, human challenge trial models, laboratory services, and HTA-licensed cryostorage and biobanking to pharmaceutical, biotech, CRO, and start-up clients.

Product overview

hVIVO is a purpose-built, full-service clinical research organization (CRO) offering an integrated platform of clinical development services. Following the January 2025 acquisition of CRS, the combined group operates under the hVIVO brand with a unified early-phase ecosystem. The product portfolio comprises six interconnected service lines: Clinical Trial Solutions (Phase I-III delivery), Drug Development Consulting (strategic guidance and regulatory affairs), Human Challenge Solutions (world-leading challenge trial models for infectious diseases), Laboratory Solutions (bioanalysis, virology, immunology, and biomarker services), Integrated Solutions (end-to-end accelerated delivery), and Biobank and Storage Solutions (HTA-licensed cryostorage). Participant recruitment is supported through dedicated platforms FluCamp (UK) and Probandeninfo (Germany), enabling access to one of Europe's largest volunteer databases. The platform enables global biopharma and emerging biotech companies to accelerate drug development from preclinical through Phase III with high-quality, actionable data.

Differentiator

Problem solved

Functional benefit

Brands

• FluCamp: Participant recruitment platform in the UK for clinical trial volunteers
• Probandeninfo

Products and services

• Clinical Trial Solutions Comprehensive Phase I–III clinical trial delivery with a focus on quality and efficiency, spanning clinical pharmacology early phase, Phase I units, Phase II/III, data management, medical monitoring, medical writing, project management, quality assurance, recruitment, regulatory affairs, clinical trial sites, and biostatistics. Target users are global pharmaceutical, biotechnology, CRO, and emerging biotech clients.
• Drug Development Consulting Strategic and scientific expertise to guide drug development, optimise trial design, and reduce risk. Covers clinical PK/PD, statistics and study design, CMC consulting, non-clinical development, regulatory affairs consultancy, due diligence, biosample project management, clinical trials legal services, and medical writing. Target users are pharmaceutical, biotech, and investor clients.
• Human Challenge Solutions Human challenge trial services that generate early efficacy data to accelerate decision-making. Includes virus production and characterisation, laboratory services, participant screening and recruitment, and clinical delivery, with specific disease models for RSV, Influenza, COVID-19, HRV, hMPV, Malaria, and Asthma & COPD. Target users are pharmaceutical and biotechnology companies developing vaccines and infectious disease therapeutics.
• Laboratory Solutions Advanced laboratory services delivering high-quality data across bioanalysis, virology, immunology, molecular biology, microbiology, PBMC processing, and biomarker analysis. Includes preclinical PK/PD studies, assay development and validation, scientific consulting and regulatory support, techniques and technology automation, and clinical trial support and kit production. Target users are pharmaceutical, biotechnology, and research clients.
• Integrated Solutions A fully connected end-to-end platform combining clinical, laboratory, recruitment, and consultancy expertise to deliver seamless, efficient clinical development. Includes Speed to Clinic Accelerator, Investor Readiness Consulting, Integrated Clinical Trial Delivery, Translational Consulting Research, Human Challenge Model Advantage, EU Expansion Strategy, and Site and Recruitment Solutions. Target users are pharmaceutical, biotech, start-up, and investor clients seeking accelerated programme delivery.
• Biobank and Storage Solutions HTA-licensed cryostorage and biobanking services with multi-temperature storage, 24/7 monitoring, full chain-of-custody management, and fast local access for biotech, pharma, and research partners. Includes cryostorage and human biological samples. Target users are biotech, pharma, and research partners.

Quantifiable outcome

• 1,900+ clinical trials successfully delivered
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CRS